Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.

Ceftolozane/tazobactam bacteremia cephalosporins pneumonia pseudomonal infections β-lactams

Journal

Expert review of anti-infective therapy
ISSN: 1744-8336
Titre abrégé: Expert Rev Anti Infect Ther
Pays: England
ID NLM: 101181284

Informations de publication

Date de publication:
26 Sep 2024
Historique:
medline: 26 9 2024
pubmed: 26 9 2024
entrez: 26 9 2024
Statut: aheadofprint

Résumé

We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024. The authors reviewed the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftolozane/tazobactam to treat patients with HABP and VABP via PubMed (up to May 2024). Ceftolozane/tazobactam was primarily used as directed therapy to treat HABP and VABP caused by In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P.

Sections du résumé

BACKGROUND UNASSIGNED
We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024.
RESEARCH DESIGN AND METHODS UNASSIGNED
The authors reviewed the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftolozane/tazobactam to treat patients with HABP and VABP via PubMed (up to May 2024).
RESULTS UNASSIGNED
Ceftolozane/tazobactam was primarily used as directed therapy to treat HABP and VABP caused by
CONCLUSIONS UNASSIGNED
In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P.

Identifiants

DOI: 10.1080/14787210.2024.2405930 PMID: 39324660
pubmed: 39324660
doi: 10.1080/14787210.2024.2405930
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-8

Auteurs

George G Zhanel (GG)

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Rita Dhami (R)

Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada.

Melanie Baxter (M)

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Maggie Wong (M)

Department of Pharmacy, Fraser Health, Vancouver, British Columbia, Canada.

Yazdan Mirzanejad (Y)

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Justin Kosar (J)

Department of Pharmacy, Royal University Hospital, Saskatoon, Saskatchewan, Canada.

Carlos Cervera (C)

Division of Infectious Diseases, Faculty of Medicine, University of Alberta, Edmonton, Alberta, Canada.

Neal Irfan (N)

Department of Pharmacy, Hamilton Health Sciences Centre, Hamilton, Ontario, Canada.

Sergio Borgia (S)

Section of Infectious Diseases, William Osler Health System, Brampton, Ontario, Canada.

Alex Serebryanskyy (A)

Department of Pharmacy, London Health Sciences Centre, London, Ontario, Canada.

Robert Ariano (R)

Department of Pharmacy, St. Boniface General Hospital, Winnipeg, Manitoba, Canada.

Michel Savoie (M)

Department of Pharmacy, CIUSSS de l'Est-de-l'Île-de-Montréal, Montreal, Quebec, Canada.

Carlo Tascini (C)

Infectious Diseases Clinic, DAME, Udine University Hospital, Udine, Italy.

Andrew Walkty (A)

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

James A Karlowsky (JA)

Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.

Classifications MeSH